← FDA DRUG APPROVALS

FDA NDA · NDA016980

LITHOTABS

Sponsor: SOLVAY

APPLICATION
NDA016980
TYPE
NDA
ORIGINAL APPROVAL
1972-04-24
LATEST ACTION
1994-06-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LITHOTABSDiscontinued
LITHIUM CARBONATE 300MG · TABLET · ORAL

Approval history

1994-06-28Manufacturing (CMC) · Supplement 22 · standardAP
1994-03-25Manufacturing (CMC) · Supplement 26 · standardAP
1994-03-25Manufacturing (CMC) · Supplement 24 · standardAP
1990-04-13Manufacturing (CMC) · Supplement 21 · standardAP
1990-04-11Manufacturing (CMC) · Supplement 20 · standardAP
1984-12-19Labeling · Supplement 17 · standardAP
1984-11-15Manufacturing (CMC) · Supplement 16 · standardAP
1983-01-21Manufacturing (CMC) · Supplement 15 · standardAP
1982-07-23Manufacturing (CMC) · Supplement 12 · standardAP
1982-02-04Labeling · Supplement 14 · standardAP
1980-10-02Labeling · Supplement 11 · standardAP
1980-03-28Manufacturing (CMC) · Supplement 6 · standardAP
1979-02-13Labeling · Supplement 8 · standardAP
1978-01-30Labeling · Supplement 7 · standardAP
1976-03-19Labeling · Supplement 3 · standardAP
1972-04-24Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →